✦ LIBER ✦

GSK-3 IS A POTENTIAL THERAPEUTIC TARGET FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC): PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION

✍ Scribed by Kawazoe, Hisashi; Bilim, Vladimir; Yuuki, Kaori; Muto, Akinori; Ougolkov, Andrei V; Billadeau, Daniel D; Oya, Mototsugu; Motoyama, Teiichi; Tomita, Yoshihiko

Book ID: 123486361
Publisher: Lippincott Williams and Wilkins
Year: 2009
Tongue: English
Weight: 92 KB
Volume: 181
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(09)60439-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

28 NUCLEAR FACTOR KAPPA B IS THE MAIN DO

28 NUCLEAR FACTOR KAPPA B IS THE MAIN DOWNSTREAM TARGET OF THE AKT SURVIVAL PATHWAY IN HUMAN RENAL CELL CARCINOMA (RCC): EVIDENCE FOR A NEW REGULATORY LOOP WITH GLYCOGEN SYNTHASE KINASE-3 AND IDENTIFICATION OF POTENTIAL THERAPEUTIC CANDIDATES

✍ C. Sourbier; S. Danilin; V. Lindner; S. Rothhut; J.J. Helwig; D. Jacqmin; H. Lan 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 317 KB

SP232 – Stat3 as a therapeutic target fo

SP232 – Stat3 as a therapeutic target for endothelial cells in the treatment of head and neck squamous cell carcinoma

✍ Jonah Klein; Seungwon Kim 📂 Article 📅 2009 🏛 SAGE Publications 🌐 English ⚖ 72 KB

NPM-ALK modulates the p53 tumour suppres

NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies

✍ Y. Cui; A. Kerby; F.K.E. McDuff; S.D. Turner 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Efficacy of everolimus in second- and th

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).

✍ Buchler, Tomas; Bortlicek, Zbynek; Poprach, Alexandr; Kubackova, Katerina; Kiss, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 327 KB